GeneDx Holdings Corp. and Zevra Therapeutics have entered into a new diagnostic partnership that will provide a sponsored genetic testing program for patients suspected of having Niemann–Pick disease type C (NPC). Under the agreement, Zevra will provide financial support for GeneDx’s ExomeDx™ test, which is designed to identify pathogenic variants in the NPC1 and NPC2 genes. Eligible patients will receive the test with a turnaround time of approximately three weeks, and the program will be available to clinicians across the United States.
GeneDx’s Infinity™ dataset, the world’s largest rare‑disease genomic database, underpins the partnership by enabling rapid, high‑confidence variant interpretation. The company’s focus on expanding its exome and genome testing services has positioned it as a leader in rare‑disease diagnostics, and the NPC program extends its reach into the neuromuscular and metabolic disease markets where early diagnosis can improve treatment outcomes and payer reimbursement.
Zevra Therapeutics, the developer of the approved NPC therapy MIPLYFFA, has recently reported strong Q4 and full‑year 2025 financial results, with revenue of $34.1 million and an earnings per share of $0.19. The company’s robust financial performance, driven largely by MIPLYFFA sales, provides the resources to support the diagnostic partnership and reinforces its commitment to expanding access to care for NPC patients.
Lisa Gurry, Chief Business Officer at GeneDx, said, "When a disease is progressive and treatable, every day matters. Through our partnership with Zevra we are removing barriers to high‑quality exome sequencing so clinicians can reach answers faster, confirm diagnoses with precision, and identify patients earlier. Our partnership programs are fueled by the GeneDx Infinity™ dataset – the world's largest rare‑disease genomic dataset – enabling biopharma partners to better understand disease biology, and accelerate the patient journey from diagnosis to treatment. This is how we translate genomic insight into transformative, real‑world impact for patients." Joshua Schafer, Zevra’s Chief Commercial Officer, added, "NPC is a devastating disease that is frequently underrecognized, often leading to delays in diagnosis and treatment. This strategic partnership with GeneDx will enhance access to genetic testing and supports physicians in identifying NPC patients earlier, enabling more timely and informed clinical decision‑making."
The partnership is expected to shorten the diagnostic odyssey for NPC patients, allowing earlier initiation of MIPLYFFA and potentially improving clinical outcomes. By combining GeneDx’s rapid, high‑accuracy testing platform with Zevra’s therapeutic pipeline and financial backing, the collaboration creates a comprehensive ecosystem that supports patients from diagnosis through treatment, strengthening both companies’ positions in the rare‑disease market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.